Please ensure Javascript is enabled for purposes of website accessibility

CDC: Cancer Death Rates Are Declining

By Prosper Junior Bakiny - Mar 12, 2020 at 4:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Newer treatments have made an impact.

Cancer continues to be one of the leading causes of death in the U.S. and worldwide. However, the Centers for Disease Control and Prevention (CDC) revealed some good news on that front in its latest annual report: Cancer death rates declined from 2001 to 2017 in the U.S.

In particular, between 2013 and 2017, the death rate for lung cancer -- the leading cause of cancer death globally -- decreased by 4.8% per year among men and by 3.7% per year among women. Overall, death rates declined for most forms of cancer and in all demographic groups. While this was excellent news, the report also emphasized that more needs to be done to keep that trend going. 

Doctor wearing a lab coat giving a thumbs up.

Image Source: Getty Images.

Credit to big pharma

Dozens of drugmakers have made significant contributions in the fight against cancer in recent years. For instance, pharma giant Merck (MRK -1.45%) markets Keytruda, which is now approved as a treatment for small cell lung cancer, head and neck cancer, and liver cancer, among many others.  Keytruda is still being evaluated as a treatment for many others, and will likely see some great days ahead: The blockbuster is projected to become the world's best-selling drug within the next few years.

Bristol Myers Squibb (BMY -0.95%) also has an exciting lineup of cancer treatments, including products such as Opdivo, which is approved for melanoma (skin cancer), lung cancer, kidney cancer, and others.  It also markets Revlimid, which is used to treat multiple myeloma. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$91.17 (-1.45%) $-1.34
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$77.00 (-0.95%) $0.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.